SG Americas Securities
RLMD icon

SG Americas Securities’s Relmada Therapeutics RLMD Stock Holding History

SG Americas Securities’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,320
Closed -$53K – 3245
2024
Q1 		$53K Buy
+11,320
New +$54.5K ﹤0.01% 2755
2022
Q4 		– Sell
-40,890
Closed -$1.51M – 3329
2022
Q3 		$1.51M Buy
40,890
+20,218
+98% +$560K 0.02% 740
2022
Q2 		$393K Sell
20,672
-84,145
-80% -$1.84M ﹤0.01% 2163
2022
Q1 		$2.83M Sell
104,817
-49,633
-32% -$1.03M 0.02% 698
2021
Q4 		$3.48M Buy
154,450
+147,653
+2,172% +$3.28M 0.02% 687
2021
Q3 		$178K Buy
+6,797
New +$182K ﹤0.01% 3310
2021
Q1 		– Sell
-17,034
Closed -$546K – 3515
2020
Q4 		$546K Sell
17,034
-44,919
-73% -$1.54M ﹤0.01% 1917
2020
Q3 		$2.33M Buy
61,953
+54,281
+708% +$2.1M 0.01% 651
2020
Q2 		$343K Buy
+7,672
New +$324K ﹤0.01% 2417

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities's RLMD Position: Q2 2024 in Review

SG Americas Securities sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 11,320 shares — an estimated $53K sold.

SG Americas Securities first reported a position in RLMD in Q2 2020 and held it in 9 quarters. The position peaked at $3.48M in Q4 2021. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • SG Americas Securities reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 11,320 Relmada Therapeutics shares in Q2 2024, an estimated $53K.
  • SG Americas Securities first reported a position in Relmada Therapeutics in Q2 2020 and held it in 9 quarters.
  • SG Americas Securities's Relmada Therapeutics position peaked at $3.48M in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.